MEMPHIS, Tenn.--(BUSINESS WIRE)--Smith & Nephew, Inc.’s (NYSE: SNN) (LSE: SN) Orthopaedic Reconstruction business today announced FDA clearance for Smith & Nephew’s JOURNEY™ Bi-Cruciate Stabilized (BCS) Knee System, the GENESIS™ II Total Knee System and the LEGION™ Revision Knee System product lines for gender specificity product requirements. This gives Smith & Nephew the largest breadth of knee products cleared for gender specific attributes, affirming the company as market leader with a range of customized products to meet changing needs of active, informed patients.
